Delving into the Latest Updates on Chengdian (Suzhou) Biopharmaceutical Co. Ltd. with Synapse

Overview

Tags

Neoplasms

Hemic and Lymphatic Diseases

Immune System Diseases

Antibody fusion proteins

Biological products

Autologous CAR-T

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Hemic and Lymphatic Diseases	3
Immune System Diseases	3
Infectious Diseases	1

Top 5 Drug Type	Count

Biological products	1
Autologous CAR-T	1
Antibody fusion proteins	1
CAR-T	1

Top 5 Target	Count

IL-21R x PD-1	1
CD19 x PD-1	1
BCMA x IL-21R x PD-1	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

3

Phase 1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CD-001 ( IL-21R x PD-1 )	Advanced Malignant Solid Neoplasm More	Phase 1
PD-1Ab21-CD19CAR-T(Chengdian Biopharmaceutical) ( CD19 x PD-1 )	CD19 Expressing Malignancies More	Early Phase 1
CD003 ( BCMA x IL-21R x PD-1 )	Multiple Myeloma More	Early Phase 1
CD-002	Solid tumor More	Preclinical